| Lifetime health gain (QALYs) | Lifetime intervention costs to Government ($billion) | Lifetime intervention costs to Patients ($billion) | Lifetime treatment costs averted ($billion) | Cost-effectiveness* ($/QALY) |
---|---|---|---|---|---|
Current practice | 270,000 (220,000 to 310,000) | $12 ($12 to $12) | $2.6 ($2.6 to $2.6) | -$3.4 (−$4.4 to -$2.4) | $41,000 ($34,000 to $52,000) |
Existing single risk factor-based guidelines | 180,000 (120,000 to 240,000) | $7.4 ($5.1 to $9.9) | $3.5 ($2.4 to $4.7) | -$2.3 (−$3.4 to -$1.3) | $49,000 ($40,000 to $60,000) |
Absolute risk (≥15%) | 67,000 (44,000 to 91,000) | $1.3 ($0.9 to $1.8) | $0.8 ($0.5 to $1.0) | -$0.7 (−$1.0 to -$0.4) | $21,000 ($17,000 to $26,000) |
Absolute risk (≥10%) | 150,000 (97,000 to 200,000) | $3.5 ($2.4 to $4.6) | $1.9 ($1.3 to $2.6) | -$1.5 (−$2.3 to -$0.9) | $27,000 ($22,000 to $32,000) |
Absolute risk (≥5%) | |||||
– including statins <10% | 330,000 (220,000 to 450,000) | $10.0 ($7.0 to $14.0) | $5.5 ($3.8 to $7.4) | -$3.7 (−$5.7 to -$2.2) | $37,000 ($31,000 to $44,000) |
– excluding statins <10% | 290,000 (190,000 to 390,000) | $6.5 ($4.5 to $8.6) | $4.3 ($2.9 to $5.7) | -$3.2 (−$4.8 to -$1.9) | $27,000 ($21,000 to $33,000) |
Absolute risk (≥5%) assuming the cheaper price of statins in New Zealand | |||||
– including statins <10% | 330,000 (220,000 to 450,000) | $5.1 ($3.5 to $6.8) | $3.7 ($2.6 to $5.0) | -$3.7 (−$5.7 to -$2.2) | $16,000 ($12,000 to $20,000) |
– excluding statins <10% | 290,000 (190,000 to 390,000) | $4.7 ($3.3 to $6.3) | $3.6 ($2.5 to $4.8) | -$3.2 (−$4.8 to -$1.9) | $18,000 ($14,000 to $24,000) |